AI Eye-Tracker could let macular patients monitor vision at home

NCT ID NCT07255885

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new device called CRYSTALSIGHT that uses eye-tracking and artificial intelligence to monitor macular diseases like age-related macular degeneration and diabetic retinopathy. Twenty participants used the device at home to see if it could accurately track eye movements compared to a standard clinic tool. The goal is to develop a convenient way for patients to monitor their condition remotely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CRYSTALSIGHT eye-tracking device
What this could lead to
If successful, this could lead to a convenient home monitoring tool for macular disease, reducing the need for frequent clinic visits.
What could go wrong
This is a small, early-stage study with only 20 participants. The device may not be as accurate as clinic-based tests, and home use may have technical or user errors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGED-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tan Tock Seng Hospital

    Singapore, 308433, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.